Teleflex (TFX) AI Stock Analysis

• Market Cap: $4.77B
• Dividend Yield: 1.11%
• Average Volume (3M): 936.81K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: 5.43%
• EPS Growth: -245.18%
• Country: US
• Employees: 14,100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.93
• Shares Outstanding: 44,200,560
• 10 Day Avg. Volume: 790,011
• 30 Day Avg. Volume: 936,806
• PEG Ratio: <0.01
• Price to Book (P/B): 1.74
• Price to Sales (P/S): 2.73
• P/FCF Ratio: 22.19
• Enterprise Value/Market Cap: 1.49
• Enterprise Value/Revenue: 2.39
• Enterprise Value/Gross Profit: 4.49
• Enterprise Value/Ebitda: 64.41
• 1Y Price Target: $133.33
• Price Target Upside: 22.32% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 6
• EPS Forecast (FY): 8.18
• Revenue Forecast (FY): $2.53B

• Rating: 47 Neutral
• Price Target: $108.00 ▼(-0.92% Downside)
• Action: Reiterated Date: 03/18/26
• Date: Action: Reiterated 03/18/26

The score is primarily pressured by the TTM financial inflection (large loss, steep revenue decline, and negative free cash flow) and weak technical momentum. This is partially offset by earnings-call visibility into a strategic reset with pro forma growth guidance and a path to longer-term margin recovery, plus modest dividend support despite negative P/E.

Positive Factors

Large divestiture proceeds for capital allocation

The expected ~$1.8B of after-tax divestiture proceeds is a structural liquidity and capital-allocation catalyst: using proceeds to retire debt and repurchase shares materially reduces leverage, lowers interest burden, and enhances financial flexibility for reinvestment and future M&A once transactions close.

Consistent pro forma revenue growth

Mid-single-digit pro forma growth shows underlying demand resilience in Teleflex's core critical-care consumables and devices. Durable, recurring procedural usage of single-use products supports steady revenue expansion, improving visibility for cash generation and capacity to fund R&D and margin recovery.

Planned step-up in R&D investment

A sustainable R&D increase to ~8% of sales signals a strategic, long-term emphasis on clinical differentiation and new product launches. For a medical-device business, sustained innovation supports pricing power, tighter competitive moats, and durable addressable-market growth beyond short-term volume cycles.

Negative Factors

Sharp TTM financial deterioration

A severe TTM drop in revenue and swing to a large net loss with negative free cash flow materially weakens operational resilience. This reduces internal funding capacity for investments and raises reliance on transaction proceeds or external financing until margins and topline recover, increasing execution risk.

Material stranded costs and margin pressure

Persistent stranded costs and a step-down to ~19% operating margin erode profitability for at least a transitional period. Lower margins compress free cash flow generation and limit reinvestment or buybacks unless TS/MS offsets and restructuring savings fully materialize, delaying durable margin recovery.

Execution and timing risk on transactions and offsets

Key financial improvements hinge on timely divestiture closings and service agreements. Any delay defers debt reduction, interest savings and share repurchases while prolonging stranded-cost drag. This conditionality is a structural near-term risk to stated deleveraging and margin pathways.

Teleflex Business Overview & Revenue Model

Company Description

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

How the Company Makes Money

Teleflex primarily makes money by selling disposable and single-use medical devices and related consumables to hospitals and healthcare providers. Revenue is generated from product sales across its major therapy and procedure areas (e.g., vascular access catheters and access systems; anesthesia and airway devices; interventional and endovascular access products; urology catheters and continence care products; and surgical products), with demand tied to procedure volumes and ongoing clinical utilization because many items are used once and repurchased continually. The company sells through a mix of direct sales teams (particularly in larger developed markets) and third-party distributors (often in smaller or emerging markets), and typically earns revenue upon shipment or delivery under customer purchase orders. Pricing and growth are influenced by hospital value-analysis processes, group purchasing organizations, tender activity in certain geographies, product innovation/clinical differentiation, and the company’s ability to maintain broad distribution and regulatory clearances. Specific revenue breakdowns by product line, contract terms, and partnership economics not publicly detailed in this prompt are null.

Teleflex Financial Statement Overview

Summary

Financials show a sharp TTM deterioration: revenue fell to about $2.0B (down ~37.5%), net income swung to a large loss (about -$906M), operating cash flow dropped to ~$96M, and free cash flow turned negative (~-$29M). While the balance sheet still has meaningful equity (~$3.12B) and lower absolute debt, the earnings and cash-flow break meaningfully raises near-term quality and visibility risk.

Income Statement

Results deteriorated sharply in TTM (Trailing-Twelve-Months): revenue fell to ~$2.0B (down ~37.5%) and profitability swung deeply negative (net income about -$906M, net margin ~-10%). This is a major break from the prior multi-year pattern of solid gross margins (~52–56%) and positive earnings (2020–2024), suggesting a large non-recurring hit and/or significant operating pressure. While gross margin remains relatively resilient in TTM (~53.7%), the collapse in earnings and the steep revenue decline meaningfully weaken the income statement profile versus recent years.

Balance Sheet

The balance sheet shows moderate leverage and a sizable equity base, but it weakened in TTM (Trailing-Twelve-Months). Debt fell sharply (to ~$184M from ~$1.76B in 2024), yet debt-to-equity is reported higher in TTM (~0.72 vs ~0.41 in 2024), implying either reporting differences or equity/structure impacts that reduce clarity. Total assets remained large (~$6.95B) and equity (~$3.12B) provides a buffer, but returns to shareholders turned negative in TTM (return on equity ~-8%), reflecting the earnings drawdown and lowering overall balance-sheet quality despite the reduced absolute debt.

Cash Flow

Cash generation weakened materially in TTM (Trailing-Twelve-Months). Operating cash flow dropped to ~$96M from ~$636M in 2024, and free cash flow turned negative (about -$29M) after being strongly positive in prior years. Cash conversion also softened: operating cash flow covered only ~51% of net income in TTM, and the negative free cash flow raises concerns around near-term funding flexibility and reinvestment capacity. The positive history of strong free cash flow (2020–2024) is a support, but the current TTM step-down is significant.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.99B	3.05B	2.97B	2.79B	2.81B
Gross Profit	1.12B	1.70B	1.65B	1.53B	1.55B
EBITDA	302.51M	433.62M	761.21M	730.77M	853.80M
Net Income	-905.64M	69.67M	356.33M	363.14M	485.37M
Balance Sheet
Total Assets	6.95B	7.10B	7.53B	6.93B	6.87B
Cash, Cash Equivalents and Short-Term Investments	393.26M	306.16M	222.85M	292.03M	445.08M
Total Debt	2.73B	1.76B	1.93B	1.83B	1.97B
Total Liabilities	3.82B	2.82B	3.09B	2.91B	3.12B
Stockholders Equity	3.12B	4.28B	4.44B	4.02B	3.75B
Cash Flow
Free Cash Flow	245.44M	509.31M	419.20M	262.95M	579.80M
Operating Cash Flow	340.68M	635.74M	510.64M	342.14M	651.42M
Investing Cash Flow	-849.19M	-99.36M	-621.23M	-257.94M	156.74M
Financing Cash Flow	611.54M	-421.93M	38.54M	-217.51M	-715.82M

Teleflex Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 109.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TFX, the sentiment is Negative. The current price of 109 is below the 20-day moving average (MA) of 114.00, below the 50-day MA of 109.75, and below the 200-day MA of 117.71, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 44.25 is Neutral, neither overbought nor oversold. The STOCH value of 10.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TFX.

Teleflex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LMAT	78 Outperform	$2.52B	31.80	15.58%	0.95%	13.07%	27.98%
MMSI	68 Neutral	$4.06B	40.58	8.52%	―	11.49%	-2.89%
HAE	67 Neutral	$2.77B	20.99	20.26%	―	-2.45%	41.50%
BLCO	60 Neutral	$5.68B	-16.79	-4.69%	―	6.23%	17.53%
ICUI	57 Neutral	$3.09B	4,802.44	0.04%	―	-0.81%	93.27%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TFX	47 Neutral	$4.77B	-6.01	-23.70%	1.11%	5.43%	-245.18%

Teleflex Corporate Events

Teleflex Clears Key Antitrust Hurdle for OEM Divestiture

Teleflex reported that, on December 9, 2025, it entered into an Equity Purchase Agreement to sell its Original Equipment Manufacturing and Development Services business to Lotus US Bidco Inc., an affiliate of Montagu Private Equity and Kohlberg & Co. The Hart-Scott-Rodino antitrust waiting period for this transaction expired at 11:59 p.m. Eastern Time on March 13, 2026, clearing a key regulatory hurdle.

The OEM transaction is now expected to close in the third quarter of 2026, subject to remaining regulatory approvals and customary conditions. On the same date in December 2025, Teleflex also signed a separate Equity Purchase Agreement to divest its Acute Care and Interventional Urology businesses to Intersurgical Limited, underscoring a broader portfolio reshaping that could materially alter the company’s operational focus and market positioning.

The most recent analyst rating on (TFX) stock is a Buy with a $155.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.

Teleflex Launches Multi-Year Restructuring to Support Divestitures

On February 23, 2026, Teleflex’s board approved a multi‑year restructuring tied to its planned strategic divestitures, aiming to realign its global organization and supply chain, cut stranded costs and rationalize capital assets, largely through workforce reductions. The program, expected to be substantially complete by mid‑2028, carries estimated restructuring and related charges of $31 million to $37 million, mostly cash outlays, and is projected to deliver annual pre‑tax savings of $48 million to $52 million once fully implemented, beginning to benefit results in 2026.

The company reported 2025 revenue from continuing operations of $1.99 billion, up more than 17% year on year, with adjusted EPS also improving, and issued 2026 guidance that builds in $90 million of stranded costs while excluding anticipated offsets from transition and manufacturing services tied to the divested units. Management framed the restructuring and divestitures as part of a broader portfolio transformation, with the two planned divestiture deals expected to close in the second half of 2026 and provide after‑tax proceeds earmarked largely for share repurchases and debt reduction, positioning Teleflex to enhance profitability and long‑term shareholder value after the transition period.

The most recent analyst rating on (TFX) stock is a Hold with a $116.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.

Teleflex completes CEO transition and separation agreement

Teleflex announced that Liam J. Kelly departed from his roles as president and chief executive officer effective at the end of the day on January 7, 2026, and subsequently resigned from the board on January 23, 2026, marking a completed leadership transition at the company. In connection with his departure, Teleflex entered into a separation agreement on January 23, 2026, under which Kelly will receive the benefits associated with a termination without cause as outlined in his existing severance agreement, including lump-sum outplacement benefits and treatment of outstanding equity awards, contingent upon his release of claims in favor of the company and its affiliates, clarifying the financial and governance implications of the executive change for stakeholders.

The most recent analyst rating on (TFX) stock is a Hold with a $106.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.

Teleflex Announces CEO Transition Amid Strategic Portfolio Shift

Teleflex announced a major leadership transition effective January 7–8, 2026, with long-time Chairman, President and CEO Liam Kelly departing and board member Stuart Randle, a veteran medical device executive with more than 35 years’ industry experience and a Teleflex director since 2009, stepping in as interim president and CEO. Lead independent director Stephen Klasko was appointed independent chair of the board, while the board engaged Spencer Stuart to search for a permanent chief executive, and Randle’s interim role was formalized through a short-term employment letter that includes a substantial monthly stipend and a $1.5 million restricted stock grant; Kelly, subject to executing a release of claims, is eligible for severance and equity vesting under his existing agreements. The leadership reshuffle comes as Teleflex pursues a strategic transformation following the announced sale of its Acute Care, Interventional Urology and OEM businesses to sharpen its focus on core critical care and high-acuity markets, and it coincided with a downgrade to preliminary full-year 2025 revenue expectations to $3.270 billion–$3.278 billion from prior guidance of $3.305 billion–$3.320 billion, reflecting softer demand for intra-aortic balloon pumps and catheters in the U.S. and Asia, OEM order delays and lower volumes in certain portfolio segments, developments that underscore both operational headwinds and the execution risk around its portfolio repositioning for investors and other stakeholders.

The most recent analyst rating on (TFX) stock is a Hold with a $135.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.